Company Overview

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a biopharmaceutical company focused on the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company operates primarily in the healthcare and biotechnology sectors, with an emphasis on chronic liver, lung, and kidney diseases. Gyre’s core commercial and development activities are centered around anti-fibrotic therapeutics, particularly in the Chinese market, while also advancing pipeline assets targeting metabolic dysfunction-associated steatohepatitis (MASH), idiopathic pulmonary fibrosis (IPF), and related conditions.

The company evolved from a reverse merger involving Catalyst Biosciences, Inc. and entities affiliated with Gyre Pharmaceuticals. Through this transaction, Gyre Therapeutics acquired interests tied to China-based pharmaceutical operations and expanded its focus toward fibrosis-related drug development and commercialization. A central strategic asset is pirfenidone, an anti-fibrotic compound marketed in China for IPF through affiliated operations. Gyre positions itself through established commercialization infrastructure in China, access to fibrosis-focused intellectual property and development programs, and integration between clinical development and regional pharmaceutical distribution capabilities.

Business Operations

Gyre Therapeutics generates revenue through pharmaceutical product sales, licensing arrangements, and development activities associated with fibrosis therapies and related pharmaceutical products. Its operations include both commercial-stage products and clinical-stage development programs. The company’s principal operating activities are connected to Gyre Pharmaceuticals Co., Ltd., which manages manufacturing, commercialization, and distribution activities in China. Key revenue drivers have included pirfenidone-based therapies and other prescription pharmaceutical products distributed through hospital and healthcare networks.

The company maintains operations across both the United States and China, with research, regulatory, and business development functions extending internationally. Gyre controls pharmaceutical manufacturing and commercialization assets through affiliated subsidiaries and maintains intellectual property and development rights tied to fibrosis-related therapeutics. Its operational structure also includes collaboration arrangements with research institutions and healthcare providers supporting clinical trials and product commercialization. Public filings indicate that the company continues to invest in pipeline expansion targeting liver fibrosis, pulmonary disease, and inflammatory conditions.

Strategic Position & Investments

Gyre Therapeutics’ strategic direction is focused on expanding its fibrosis and inflammatory disease portfolio through clinical development, commercialization scale-up, and selective investment in therapeutic technologies. The company has prioritized advancing programs related to MASH-associated fibrosis, IPF, and chronic organ inflammation, while leveraging existing commercial infrastructure in China. Management has emphasized the combination of commercial-stage revenue generation with development-stage pipeline expansion as a core element of long-term strategy.

Major strategic assets include interests in Gyre Pharmaceuticals Co., Ltd. and associated commercialization operations in China. The reverse merger transaction involving Catalyst Biosciences, Inc. significantly reshaped the company’s business model and asset base. Gyre has also highlighted investments in research collaborations, regulatory advancement initiatives, and clinical development programs targeting emerging fibrosis indications. Public disclosures indicate ongoing evaluation of additional licensing, partnership, and acquisition opportunities aligned with fibrosis therapeutics and specialty pharmaceutical markets.

Geographic Footprint

Gyre Therapeutics maintains a cross-border operational footprint with activities concentrated in China and the United States. The company’s headquarters functions and public market presence are tied to the United States, while a substantial portion of commercial pharmaceutical operations, manufacturing activities, and healthcare distribution infrastructure are located in China. The Chinese market represents a major source of operational activity due to existing pharmaceutical commercialization capabilities and established physician and hospital relationships.

The company’s market presence extends primarily across Asia and North America, with strategic interest in broader global fibrosis markets. Through affiliated pharmaceutical operations in China, Gyre participates in one of the world’s largest pharmaceutical and respiratory disease treatment markets. Its international strategy includes clinical development alignment with global regulatory standards and potential expansion opportunities in additional jurisdictions where fibrosis therapies represent unmet medical needs.

Leadership & Governance

Gyre Therapeutics is led by executives with backgrounds in biotechnology, pharmaceutical commercialization, finance, and cross-border healthcare operations. Following the merger that formed the current company structure, leadership has emphasized building an integrated fibrosis-focused biopharmaceutical organization combining commercial operations in China with clinical development and capital markets access in the United States. Governance oversight includes a board structure consistent with publicly traded biotechnology companies listed in the United States.

Key executives identified in public company disclosures include:

• Han Ying – Chief Executive Officer
• William Lee – Chief Financial Officer
• Wei-Wu He – Executive Chairman
• Peter M. Bauer – Independent Director
• Jinsheng Guo – Director

Management communications and public filings indicate a strategic focus on long-term growth through fibrosis therapeutics, disciplined clinical development, and expansion of commercial pharmaceutical operations. Certain executive role details may evolve over time based on corporate filings and governance updates.